Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more
Shanghai Medicilon Inc (688202) - Total Liabilities
Latest total liabilities as of June 2025: CN¥749.64 Million CNY
Based on the latest financial reports, Shanghai Medicilon Inc (688202) has total liabilities worth CN¥749.64 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Medicilon Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Shanghai Medicilon Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Medicilon Inc Competitors by Total Liabilities
The table below lists competitors of Shanghai Medicilon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Synsam AB
ST:SYNSAM
|
Sweden | Skr5.42 Billion |
|
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd
SHE:000922
|
China | CN¥4.54 Billion |
|
Beijing Haitian Ruisheng Science Technology Ltd
SHG:688787
|
China | CN¥116.34 Million |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
USA | $5.06 Billion |
|
Matthews International Corporation
NASDAQ:MATW
|
USA | $1.01 Billion |
|
OVS S.p.A.
LSE:0R5R
|
UK | €1.82 Billion |
|
Jiangsu Shuangxing Color Plastic New Materials Co Ltd
SHE:002585
|
China | CN¥3.89 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Shanghai Medicilon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Medicilon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Medicilon Inc (2016–2024)
The table below shows the annual total liabilities of Shanghai Medicilon Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥683.10 Million | -9.53% |
| 2023-12-31 | CN¥755.07 Million | +3.89% |
| 2022-12-31 | CN¥726.80 Million | +55.94% |
| 2021-12-31 | CN¥466.06 Million | +103.81% |
| 2020-12-31 | CN¥228.67 Million | +79.02% |
| 2019-12-31 | CN¥127.73 Million | +2.13% |
| 2018-12-31 | CN¥125.06 Million | +22.27% |
| 2017-12-31 | CN¥102.29 Million | +3.52% |
| 2016-12-31 | CN¥98.81 Million | -- |